(PRWEB) September 05, 2015
Predictive Biology, Inc. (“Predictive”) has signed a research agreement with Takeda Pharmaceuticals to investigate inflammatory responses in the central nervous system (CNS). The two-year research collaboration will use Predictive’s panel of more than 1,000 genetically diverse stem cell lines to identify causal genes that underlie drug response in neuronal cells, with the aim of discovering new drug targets for CNS disorders.
Inflammation is a distinguishing trait of many major neurological diseases, but the mechanisms by which neuroactive drugs affect inflammation in the CNS, and the genetic basis of why different people may respond differently to these drugs, is poorly understood. This research collaboration brings together pharmacology, stem cell biology and genetics to expose these mechanisms, which may in turn drive the development of new CNS therapeutics.
“We are very excited to work with Takeda on this innovative approach to identifying genes and pathways of drug action. Unlike other genome-scale approaches like transcriptomics or proteomics, our vitro genetics technology is designed to identify just the causal factors involved in drug response,” said Dr. Ted Choi, President and Chief Scientific Officer at Predictive Biology.
About Predictive Biology, Inc.
Predictive Biology is a privately held company located in Carlsbad, CA. Our mission is to develop more predictive technologies for drug discovery, regenerative medicine and environmental toxicology. We partner with pharmaceutical companies, biotechnology companies and academic labs to conduct leading edge research programs in preclinical pharmacology and stem cell sciences.